Abstract:Alcoholic hepatitis (AH) is an acute and severe form of alco1holic liver disease associated with high morbidity and mortality of 30-50% worldwide, severity ranging from asymptomatic derangement of liver biochemistries to fulminant liver failure or death. Rapidly progressing jaundice and coagulopathy in prolonged excessive alcohol abusers with or without fever, malnutrition, and tender liver are the clinical hallmarks. The prognostic models (Model for end-stage liver disease, Maddrey's discriminant function [MDF], age, serum bilirubin, INR, creatinine [ABIC], Glasgow Alcoholic Hepatitis Score [GAHS], Lille's Score) not only predict the short term mortality, but also guide the clinicians to choose appropriate specific therapy (corticosteroid or pentoxifylline) and as a stopping rule if there is no significant benefits of it. MDF Score is commonly followed in clinical practice, score of >32 would predict short term mortality of around 20-30% at 1 month and 30-40% within 6 months after presentation. The GAHS on day 1 can predict 28 day overall survival outcome accuracy of 81%, which is comparatively higher than MDF Score. Moreover, ABIC Score categorizes risk of deaths (based on 90 days) into low risks (0%), intermediate risk (30%), and high risk (75%). Corticosteroid and pentoxifylline have significant benefits in decreasing mortality (corticosteroid improves survival on 28 day and 84 day of 78% and 59%) in severe disease state (MDF >32 or Lille's Score >0.45 or GAHS >9). Corticosteroid is the initial treatment of choice with infections screening before initiating; however, pentoxifylline is better preferred in case of AH with severe infections and hepatorenal syndrome. Additionally, combination of corticosteroids and N-acetylcysteine decreases development of hepatorenal syndrome, infections, and short-term mortality. However, the Lille Score after corticosteroid therapy of >0.45 after day 7 indicates poor responders or >0.56 indicates null responders. Therefore, in these cases, either therapy has to be stopped or changed to pentoxifylline. In treatment failure cases, liver transplantation is the ultimate option. However, the facilitating of this service in most transplant centers is a challenge. Beside these specific therapies, alcohol abstinence and recommendation of nutritional supplements with high calorie, protein diet and vitamin E, C, thiamine regardless of other treatment plays a prime role in preventing disease progression and survival benefits even in pre and post-transplant cases.

Racial Disparities in Alcoholic Hepatitis Hospitalizations in the United States: Trends, Outcomes, and Future Projections

Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis

Risk of Mortality among Patients with Alcohol-Associated Hepatitis in the US from 2007 to 2021

S2024 Trends, Gender, and Racial Disparities in Mortality Related to Liver Diseases Associated With Substance Use Disorder in the United States: A Retrospective Analysis from 1999 to 2020

Declining Inpatient Mortality Despite Increasing Thirty-Day Readmissions of Alcoholic Hepatitis in the United States From 2010 to 2018

The Impact of Gender and Race on Outcomes for Hospitalized Hepatitis A Patients Stratified by Liver Disease Severity

A Prognostic Evaluation and Management of Alcoholic Hepatitis

Health Disparities in Time to Diagnosis and Survival Post-Diagnosis of Cirrhosis in Individuals with Alcohol Use Disorder: A Retrospective Cohort Study

S2091 Outcomes of Alcohol-Associated Hepatitis in Hospitalized Patients With Prior Bariatric Surgery: A Nationwide Analysis, 2016-2020

Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis

Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States

T1864 Early Mortality of Alcoholic Hepatitis: A Review of Data from Placebo-Controlled Clinical Trials

Emergency services utilization by patients with alcohol‐associated hepatitis: An analysis of national trends

Demographic inequities exist and influence transplant outcomes in liver transplantation for acute alcohol-associated hepatitis

Alcoholic hepatitis: Translational approaches to develop targeted therapies

Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis

Changing landscape of alcohol‐associated liver disease in younger individuals, women, and ethnic minorities

S1857 Racial Disparities in Autoimmune Hepatitis - A Nationwide Inpatient Sample Analysis

United States-Mexico Border Disparities in Alcoholic Liver Disease Mortality

Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.